deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT00905060

HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM (HeatShock)

PHASE 2, Multi-center, Single Arm Investigation of HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

Sponsor: Agenus Inc.

Conditions Brain and Central Nervous System Tumors
Interventions HSPPC-96 Standard Surgical Resection Temozolomide
Updated 10 times since 2017 Last updated: Mar 23, 2021 Started: Jun 29, 2009 Primary completion: Jun 3, 2014 Completion: Jun 3, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00905060, this PHASE2 trial focuses on Brain and Central Nervous System Tumors and remains completed. Sponsored by Agenus Inc., it has been updated 10 times since 2009, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Dec 2019 · 18 months · monthly snapshotCompleted~Dec 2019 – ~Jan 2021 · 13 months · monthly snapshotCompleted~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshotCompleted~Apr 2021 – ~Dec 2022 · 20 months · monthly snapshotCompleted~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotCompleted~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

  5. Apr 2021 — Dec 2022 [monthly]

    Completed PHASE2

▶ Show 5 earlier versions

  1. Jan 2021 — Apr 2021 [monthly]

    Completed PHASE2

  2. Dec 2019 — Jan 2021 [monthly]

    Completed PHASE2

  3. Jun 2018 — Dec 2019 [monthly]

    Completed PHASE2

  4. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  5. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Jun 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Agenus Inc.
  • University of California, San Francisco
Data source: University of California, San Francisco

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations